CERO Therapeutics receives Nasdaq delisting notice; stock price at $0.10 or less

CERO THERAPEUTICS HOLDINGS, INC.

Nasdaq determined to delist CERO common stock due to closing bid price ≤$0.10 for 10 consecutive days.
Company has until Oct 31, 2024 to appeal; hearing request will stay suspension pending panel decision.
Company plans to propose reverse stock split at Nov 11 special meeting to regain compliance, but approval uncertain.
Prior Bid Price Cure Period until Jan 15, 2025 is rendered unavailable by Low Priced Stocks Rule.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.